Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · IEX Real-Time Price · USD
0.642
-0.018 (-2.79%)
At close: May 2, 2024, 3:58 PM
0.649
+0.007 (1.14%)
After-hours: May 2, 2024, 7:37 PM EDT
Traws Pharma Revenue
In the year 2023, Traws Pharma had annual revenue of $226.00K. Revenue in the quarter ending December 31, 2023 was $56.00K.
Revenue (ttm)
$226.00K
Revenue Growth
n/a
P/S Ratio
71.83
Revenue / Employee
$13,294
Employees
17
Market Cap
16.23M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 226.00K | - | - |
Dec 31, 2022 | 226.00K | - | - |
Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
Dec 31, 2019 | 2.18M | 955.00K | 77.77% |
Dec 31, 2018 | 1.23M | 441.00K | 56.04% |
Dec 31, 2017 | 787.00K | -4.76M | -85.81% |
Dec 31, 2016 | 5.55M | -5.91M | -51.59% |
Dec 31, 2015 | 11.46M | 10.66M | 1,332.00% |
Dec 31, 2014 | 800.00K | -3.95M | -83.17% |
Dec 31, 2013 | 4.75M | -41.44M | -89.71% |
Dec 31, 2012 | 46.19M | 44.70M | 3,006.25% |
Dec 31, 2011 | 1.49M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareCloud | 117.06M |
Flora Growth | 76.07M |
Streamline Health Solutions | 22.60M |
Avalo Therapeutics | 1.92M |
Talphera | 651.00K |
QT Imaging Holdings | 40.36K |
TRAW News
- 4 weeks ago - Traws Pharma Announces New Employee Inducement Grants - GlobeNewsWire
- 7 weeks ago - Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024 - GlobeNewsWire
- 5 months ago - Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's - GlobeNewsWire
- 5 months ago - Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference - GlobeNewsWire
- 6 months ago - Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results - GlobeNewsWire
- 6 months ago - Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023 - GlobeNewsWire
- 6 months ago - Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL - GlobeNewsWire
- 6 months ago - Onconova Expands Leadership Team with Two Key Appointments - GlobeNewsWire